30 Jun 2020 GPN Vaccines closes A$7 million Series A2 round oversubscribed with Forepont Capital Partners becoming a significant investor Adelaide, Australia, 30th June 2020 – Australian biotechnology company GPN Vaccines, which is developing a vaccine against the world’s foremost bacterial pathogen, Streptococcus pneumoniae, is pleased to announce it has raised A$7 million
1 Jun 2020 Astute Ventures makes an investment in Australia based GPN Vaccines Pty Ltd. Reasons for the investment GPN Vaccine covers all 100 Serotypes (strains) of Pneumonia and all future Serotypes. Pneumonia is a common respiratory infection, affecting approximately 450 million people a year and occurring in all parts of the world. It
1 Jun 2020 Astute Capital launches Astute Ventures LLC
Proin aliquam luctus interdum. Etiam sed erat luctus, placerat dolor vitae, interdum dolor. Interdum et malesuada fames ac ante ipsum primis in faucibus. Interdum et malesuada fames ac ante ipsum primis in faucibus. Donec feugiat rutrum purus quis elementum. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas.
